New pill hopes to quiet Parkinson's – but It's early days

NCT ID NCT07142044

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This early-stage trial tests whether an oral drug called EC5026 is safe and might ease symptoms in 18 adults with Parkinson's disease. Participants take the drug or a placebo daily for 28 days, with frequent checkups and tests. The main goal is safety, with symptom improvement explored as a secondary aim.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

EC5026 oral tablet

What this could lead to

If it works, this could point toward a new way to ease Parkinson's symptoms by targeting inflammation pathways.

What could go wrong

This is a very early, small trial (18 people) focused on safety, not proof of effectiveness. The drug may not improve symptoms or could cause side effects.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PARKINSON'S DISEASE (PD) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Parkinson disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • University of California Davis

    RECRUITING

    Sacramento, California, 95817, United States